Health

Moderna announces its COVID-19 vaccine protects against Delta variant

CAMBRIDGE, Mass. — Moderna, the Cambridge-based biotechnology company, announced Tuesday morning the new results from recent studies that showed individuals vaccinated with the Moderna COVID-19 vaccine showing activity against variants of SARS-CoV-2, or better known as the Delta variant.

“As we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves. We remain committed to studying emerging variants, generating data, and sharing it as it becomes available. These new data are encouraging and reinforce our belief that the Moderna COVID-19 Vaccine should remain protective against newly detected variants,” said Stéphane Bancel, Chief Executive Officer of Moderna. “These findings highlight the importance of continuing to vaccinate populations with an effective primary series vaccine.”

This isn’t the first variant that the Moderna COVID-19 vaccine allegedly protects against. Other variants include additional versions of the Beta variant (B.1.351, first identified in South Africa), three lineage variants of B.1.617 (first identified in India), including the Kappa (B.1.617.1) and the Delta variants (B.1.617.2); the Eta variant (B.1.525, first identified in Nigeria); and the A.23.1 and A.VOI.V2 variants first identified in Uganda and Angola.

Moderna added that it is pursuing clinical development strategies against emerging variants.

For more information on this latest study conducted by Moderna, click here.

Download the free Boston 25 News app for up-to-the-minute push alerts

>> Complete Covid-19 vaccine coverage

RESOURCES:

- Complete local and national coronavirus coverage here

- Follow us on Facebook and Twitter | Watch Boston 25 NOW

- Download our free apps for your phone and smart TV